📊 KPTI Key Takeaways
Is Karyopharm Therapeutics Inc. (KPTI) a Good Investment?
Karyopharm is technically insolvent with negative stockholders' equity of -$265.6M, signaling severe structural distress. The company is deteriorating rapidly with net income down 156.5% YoY, operating margin of -76.3%, and negative free cash flow of -$22.7M. With flat revenue growth (+0.6%) and approximately 4 quarters of cash runway remaining, the company faces acute solvency risk without dramatic operational turnaround.
Revenue is essentially flat while profitability remains deeply negative, with operating and net margins of -62% and -134% and ROA of -181% signaling severe losses relative to a small asset base. Negative shareholders’ equity, weak interest coverage, and only modest liquidity (current ratio ~1.1) create acute solvency and refinancing risk without rapid margin improvement or new capital. Persistent negative free cash flow (-52% margin) points to ongoing burn and potential dilution or restructuring pressure.
Karyopharm Therapeutics Inc. Key Strengths (KPTI)
- Maintains $90.8M in cash providing near-term liquidity runway
- Generating $35.1M in quarterly revenue indicating some product commercialization
- Pharmaceutical sector can achieve margin recovery if pipeline products achieve market adoption
- Established commercial revenue base (~$146M) with slight YoY growth
- Capex‑light model offering operating flexibility if margins improve
- Current ratio above 1x provides a limited short‑term buffer
KPTI Stock Risks: Karyopharm Therapeutics Inc. Investment Risks
- Negative stockholders' equity of -$265.6M represents technical insolvency and balance sheet insolvency
- Net income deteriorated 156.5% YoY with operating losses of -$26.8M per quarter unsustainable
- Negative free cash flow of -$22.7M with limited runway before cash depletion forces financing or restructuring
- Debt burden of $169.3M cannot be serviced from operations with interest coverage of -1.8x
- Revenue growth at +0.6% is insufficient to improve operating leverage or reduce losses
- Negative equity and liabilities far exceeding assets indicate solvency risk
- Sustained cash burn and negative interest coverage imply dependence on financing/dilution
- Flat top‑line limits operating leverage and delays path to break‑even
Key Metrics to Watch
- Quarterly cash burn rate and absolute cash balance - determines path to solvency or distress event
- Revenue growth acceleration - must exceed 10%+ YoY to justify operational losses
- Operating margin improvement trajectory - must approach breakeven within 2-3 quarters for viability
- Operating cash flow (burn/runway)
- Operating margin
Karyopharm Therapeutics Inc. (KPTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Karyopharm Therapeutics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
KPTI Profit Margin, ROE & Profitability Analysis
KPTI vs Healthcare Sector: How Karyopharm Therapeutics Inc. Compares
How Karyopharm Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Karyopharm Therapeutics Inc. Stock Overvalued? KPTI Valuation Analysis 2026
Based on fundamental analysis, Karyopharm Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Karyopharm Therapeutics Inc. Balance Sheet: KPTI Debt, Cash & Liquidity
KPTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Karyopharm Therapeutics Inc.'s revenue has declined by 30% over the 5-year period, indicating business contraction. The most recent EPS of $-18.79 indicates the company is currently unprofitable.
KPTI Revenue Growth, EPS Growth & YoY Performance
KPTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $30.0M | -$22.4M | $-1.24 |
| Q3 2025 | $38.8M | -$32.1M | $-3.82 |
| Q2 2025 | $37.9M | -$13.6M | $-2.97 |
| Q1 2025 | $30.0M | -$23.5M | $-2.77 |
| Q3 2024 | $36.0M | -$32.1M | $-0.26 |
| Q2 2024 | $37.6M | -$13.6M | $-0.20 |
| Q1 2024 | $33.1M | -$34.1M | $-0.30 |
| Q3 2023 | $36.0M | -$34.5M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Karyopharm Therapeutics Inc. Dividends, Buybacks & Capital Allocation
KPTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Karyopharm Therapeutics Inc. (CIK: 0001503802)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KPTI
What is the AI rating for KPTI?
Karyopharm Therapeutics Inc. (KPTI) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KPTI's key strengths?
Claude: Maintains $90.8M in cash providing near-term liquidity runway. Generating $35.1M in quarterly revenue indicating some product commercialization. ChatGPT: Established commercial revenue base (~$146M) with slight YoY growth. Capex‑light model offering operating flexibility if margins improve.
What are the risks of investing in KPTI?
Claude: Negative stockholders' equity of -$265.6M represents technical insolvency and balance sheet insolvency. Net income deteriorated 156.5% YoY with operating losses of -$26.8M per quarter unsustainable. ChatGPT: Negative equity and liabilities far exceeding assets indicate solvency risk. Sustained cash burn and negative interest coverage imply dependence on financing/dilution.
What is KPTI's revenue and growth?
Karyopharm Therapeutics Inc. reported revenue of $35.1M.
Does KPTI pay dividends?
Karyopharm Therapeutics Inc. does not currently pay dividends.
Where can I find KPTI SEC filings?
Official SEC filings for Karyopharm Therapeutics Inc. (CIK: 0001503802) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KPTI's EPS?
Karyopharm Therapeutics Inc. has a diluted EPS of $-1.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KPTI's fundamental grade?
Based on our AI fundamental analysis in May 2026, Karyopharm Therapeutics Inc. has a D grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KPTI stock overvalued or undervalued?
Valuation metrics for KPTI: ROE of N/A (sector avg: 15%), net margin of -63.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KPTI's AI grade for 2026?
Our dual AI analysis gives Karyopharm Therapeutics Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KPTI's free cash flow?
Karyopharm Therapeutics Inc.'s operating cash flow is $-22.7M, with capital expenditures of $0.0. FCF margin is -64.8%.
How does KPTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -63.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.08 (avg: 2).